Risk stratification of abdominopelvic failure for FIGO stage III epithelial ovarian cancer patients: Implications for adjuvant radiotherapy

Journal of Gynecologic Oncology

Volumn 24, Issue 2, 2013, Pages 146-153

  Chang, Jee Suk ^a   Koom, Woong Sub ^a   Kim, Sang Wun ^a   Kim, Sunghoon ^a   Kim, Yong Bae ^a   Kim, Young Tae ^a   Kim, Gwi Eon ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Abdominopelvic recurrences; Adjuvant radiotherapy; Epithelial ovarian cancer; Patterns of failure

Indexed keywords

CA 125 ANTIGEN; CARBOPLATIN; CISPLATIN; DOCETAXEL; PACLITAXEL;

ABDOMINOPELVIC FAILURE; ABDOMINOPELVIC FAILURE FREE SURVIVAL; ADULT; AGE; AGED; ARTICLE; BRAIN METASTASIS; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RISK; CANCER SIZE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CYTOREDUCTIVE SURGERY; DISTANT METASTASIS; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HUMAN; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MIDDLE AGED; MINIMAL RESIDUAL DISEASE; MULTIPLE CYCLE TREATMENT; OVARY CARCINOMA; OVERALL SURVIVAL; PARAAORTIC LYMPH NODE; PERITONEUM METASTASIS; POSTOPERATIVE PERIOD; TREATMENT FAILURE; UNSPECIFIED SIDE EFFECT; VERY ELDERLY;

EID: 84893149976     PISSN: 20050380     EISSN: 20050399     Source Type: Journal    
DOI: 10.3802/jgo.2013.24.2.146     Document Type: Article

References (22)

1. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:1-6.
2. Muggia FM, Braly PS, Brady MF, Sutton G, Niemann TH, Lentz SL, et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study. J Clin Oncol 2000;18:106-15.
3. Piccart MJ, Bertelsen K, James K, Cassidy J, Mangioni C, Simonsen E, et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 2000;92:699-708.
4. Pectasides D, Pectasides E. Maintenance or consolidation therapy in advanced ovarian cancer. Oncology 2006;70: 315-24.
5. Dembo AJ. Radiotherapeutic management of ovarian cancer. Semin Oncol 1984;11:238-50.
6. Jaaback K, Johnson N. Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. Cochrane Database Syst Rev 2006;(1):CD005340.
7. Hess LM, Benham-Hutchins M, Herzog TJ, Hsu CH, Malone DC, Skrepnek GH, et al. A meta-analysis of the efficacy of intraperitoneal cisplatin for the front-line treatment of ovarian cancer. Int J Gynecol Cancer 2007;17:561-70.
8. Sorbe B; Swedish-Norwegian Ovarian Cancer Study Group. Consolidation treatment of advanced (FIGO stage III) ovarian carcinoma in complete surgical remission after induction chemotherapy: a randomized, controlled, clinical trial comparing whole abdominal radiotherapy, chemotherapy, and no further treatment. Int J Gynecol Cancer 2003;13:278-86.
9. Cardenes H, Randall ME. Integrating radiation therapy in the curative management of ovarian cancer: current issues and future directions. Semin Radiat Oncol 2000; 10:61-70.
10. Barakat RR, Markman M, Randall ME. Principles and practice of gynecologic oncology. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2009.
11. Dembo AJ. Abdominopelvic radiotherapy in ovarian cancer: a 10-year experience. Cancer 1985;55(9 Suppl):2285-90.
12. Goldberg N, Peschel RE. Postoperative abdominopelvic radiation therapy for ovarian cancer. Int J Radiat Oncol Biol Phys 1988;14:425-9.
13. Carey MS, Dembo AJ, Simm JE, Fyles AW, Treger T, Bush RS. Testing the validity of a prognostic classification in patients with surgically optimal ovarian carcinoma: a 15-year review. Int J Gynecol Cancer 1993;3:24-35.
14. Dinniwell R, Lock M, Pintilie M, Fyles A, Laframboise S, Depetrillo D, et al. Consolidative abdominopelvic radiotherapy after surgery and carboplatin/paclitaxel chemotherapy for epithelial ovarian cancer. Int J Radiat Oncol Biol Phys 2005;62:104-10.
15. Rubin SC, Randall TC, Armstrong KA, Chi DS, Hoskins WJ. Ten-year follow-up of ovarian cancer patients after second-look laparotomy with negative findings. Obstet Gynecol 1999;93:21-4.
16. Greer BE, Bundy BN, Ozols RF, Fowler JM, Clarke-Pearson D, Burger RA, et al. Implications of second-look laparotomy in the context of optimally resected stage III ovarian cancer: a non-randomized comparison using an explanatory analysis: a Gynecologic Oncology Group study. Gynecol Oncol 2005;99:71-9.
17. Chung HH, Kang WJ, Kim JW, Park NH, Song YS, Chung JK, et al. Role of [18F]FDG PET/CT in the assessment of suspected recurrent ovarian cancer: correlation with clinical or histological findings. Eur J Nucl Med Mol Imaging 2007;34:480-6.
18. Sironi S, Messa C, Mangili G, Zangheri B, Aletti G, Garavaglia E, et al. Integrated FDG PET/CT in patients with persistent ovarian cancer: correlation with histologic findings. Radiology 2004;233:433-40.
19. Pan HS, Lee SL, Huang LW, Chen YK. Combined positron emission tomography-computed tomography and tumor markers for detecting recurrent ovarian cancer. Arch Gynecol Obstet 2011;283:335-41.
20. Rochet N, Sterzing F, Jensen A, Dinkel J, Herfarth K, Schubert K, et al. Helical tomotherapy as a new treatment technique for whole abdominal irradiation. Strahlenther Onkol 2008;184:145-9.
21. Kim YB, Kim JH, Jeong KK, Seong J, Suh CO, Kim GE. Dosimetric comparisons of three-dimensional conformal radiotherapy, intensity-modulated radiotherapy, and helical tomotherapy in whole abdominopelvic radiotherapy for gynecologic malignancy. Technol Cancer Res Treat 2009;8:369-77.
22. Rochet N, Sterzing F, Jensen AD, Dinkel J, Herfarth KK, Schubert K, et al. Intensity-modulated whole abdominal radiotherapy after surgery and carboplatin/taxane chemotherapy for advanced ovarian cancer: phase I study. Int J Radiat Oncol Biol Phys 2010;76:1382-9.